Low-Dose RATG with or without Basiliximab in Renal Transplantation: A Matched-Cohort Observational Study
Article 2015 en
Authors
GG
Giorgio Gentile
CS
Chiara Somma
AG
Alessia Gennarini
Abstract
1 min read
In renal transplantation, basiliximab plus peri-operative low-dose RATG more efficiently prevented allograft rejection than RATG monotherapy, and minimized steroid exposure and toxicity. AZA- vs MMF-based maintenance immunosuppression largely compensated the extra costs of basiliximab.
Norberto Perico, Paolo Cravedi, Piero Ruggenenti, Eliana Gotti, Giovanni Rota, Giuseppe Locatelli, Vincenzo Gambara, Annalisa Perna, Stefano Rota, Giuseppe Remuzzi
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.